STOCKS TELEGRAPH

Tag: SpringWorks Stock

  • SpringWorks (SWTX) Rallies In Pre-Market On Regulatory Progress

    SpringWorks (SWTX) Rallies In Pre-Market On Regulatory Progress

    The stock price of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) is rising on the US stock charts today, indicating that investors are feeling more optimistic about the recent regulatory developments. Following a steady close in the last trading session, SWTX shares increased by 7.35% to $43.94 during the pre-market session. The company’s medication approval procedure has made substantial progress, which is the main driver of this stock price spike.

    The FDA accepts the new drug application (NDA)

    The U.S. Food and Drug Administration’s (FDA) has approved of SpringWorks’ NDA, for mirdametinib for the treatment of adults and children with plexiform neurofibromas, commonly known as NF1-PN associated with neurofibromatosis type 1.

    For now, there are no effective treatment options available for this rare and debilitating condition. The NDA has been granted Priority Review, with an action deadline of February 28, 2025 under the Prescription Drug User Fee Act, or PDUFA. The FDA’s notification that it would not be conducting an advisory committee meeting to consider this application serves as additional evidence of the submission’s validity.

    European Medicines Agency (EMA) Validates SWTX’s Application

    In addition to the events in the US, SpringWorks announced that the EMA has validated the Marketing Authorization Application (MAA) for mirdametinib. This validation is crucial in order to make mirdametinib the first medication licensed for adult patients and the best available treatment for children with NF1-PN.

    Mirdametinib had already been designated as an Orphan Drug by the FDA and the European Commission, highlighting the treatment’s potential to meet unmet medical requirements in this patient group.

    Positive Clinical Trial Outcomes

    Present at the 2024 Annual Meeting of the American Society of Clinical Oncology, the study results demonstrated the safety and efficacy of mirdametinib, including its profound and persistent responses, manageable safety profile, improvements in pain and quality of life, and significant objective response rates across both adult and pediatric groups.

    Data from the pivotal Phase 2b ReNeu study, which assessed mirdametinib in individuals with NF1-associated PN aged two years and older, are included in the NDA and MAA filings. These results bolster mirdametinib’s promise as a ground-breaking treatment for NF1-PN.

  • After-Hours Recovery Of SpringWorks (SWTX) Stock

    After-Hours Recovery Of SpringWorks (SWTX) Stock

    SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) experienced a notable uptick of 16.03%, reaching $24.10 in the extended trading session on Monday. This recovery not only nullified the regular-session decline of 4.51% but also culminated in a closing figure of $20.77. The surge in SWTX stock value ensued subsequent to a momentous regulatory approval.

    SpringWorks (SWTX) disclosed that the U.S. Food and Drug Administration (FDA) has sanctioned OGSIVEO (nirogacestat), an oral gamma secretase inhibitor. This approval is specifically designated for the treatment of adult patients grappling with advancing desmoid tumors necessitating systemic intervention. Nirogacestat had previously garnered breakthrough therapy, fast track, and orphan drug designations from the FDA for desmoid tumor treatment.

    Marking a significant milestone, SpringWorks has introduced the inaugural FDA-approved therapeutic solution for individuals contending with desmoid tumors. This development addresses a longstanding need within the community for an efficacious intervention capable of not only reducing tumor size but also markedly ameliorating pain—the most debilitating symptom encountered by individuals afflicted with desmoid tumors.

    The impact of desmoid tumors on individuals’ lives is considerable, compounded by their invasive nature and a high proclivity for recurrence. OGSIVEO emerges as a pioneering therapeutic approach, supported by efficacy data showcasing substantial antitumor activity and a pronounced enhancement in desmoid tumor symptoms.

    The green light for OGSIVEO from the FDA is rooted in the outcomes of the Phase 3 DeFi trial, which featured in the March 9, 2023, edition of the New England Journal of Medicine. OGSIVEO successfully met the primary endpoint of enhancing progression-free survival (PFS), demonstrating a statistically significant 71% reduction in the risk of disease progression compared to the placebo.

    The improvements in PFS and overall response rate (ORR) favored OGSIVEO across various baseline characteristics, including sex, tumor location, tumor focality, treatment history, prior interventions, mutational status, and familial adenomatous polyposis history.

    Furthermore, OGSIVEO showcased early and sustained enhancements in patient-reported outcomes (PROs), encompassing pain, desmoid tumor-specific symptoms, physical/role functioning, and overall health-related quality of life.